Japan Tuberculosis Treatment Market Report and Forecast 2025-2034
Description
The Japan tuberculosis treatment market was valued at USD 445.20 Million in 2024, driven by the increasing incidence of tuberculosis in the region. The market is anticipated to grow at a CAGR of 4.80% during the forecast period of 2025-2034, with the values likely to reach USD 711.49 Million by 2034.
Japan Tuberculosis Treatment Market Overview
Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially impacting other organs. Tuberculosis treatment involves a multi-drug antibiotic regimen over several months to ensure complete eradication and prevent resistance. The Japan tuberculosis treatment market is supported by robust healthcare systems, aging demographics, and national efforts in disease control and prevention.
Japan Tuberculosis Treatment Market Growth Drivers
Rising Tuberculosis Incidence to Accelerate Market Growth
The increasing incidence of tuberculosis is a significant driver of market growth in Japan. As per the World Health Organization, Japan recorded a tuberculosis incidence rate of 9.3 cases per 100,000 population in 2023. This ongoing public health concern reflects the demand for effective therapies, thereby contributing to the expansion of the tuberculosis treatment market.
Japan Tuberculosis Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Deployment of Mobile X-Ray Technology Likely to Elevate the Market Value
A notable trend in the market is the deployment of mobile diagnostic technology to support international public health. In August 2024, Japan provided a mobile X-ray machine to Olongapo City, Philippines, under its Official Development Assistance initiative. This strategic collaboration highlights Japan's technological contribution and is likely to boost market growth through innovation and global outreach.
Innovative Drug Development and Diagnostic Advancements to Augment the Japan Tuberculosis Treatment Market Demand
The Japan tuberculosis treatment market is experiencing a positive trend driven by historic innovation and ongoing diagnostic efforts. Since launching Pasnal and Iscotin in the mid-20th century, Daiichi Sankyo has remained a pioneer in tuberculosis drug development. These sustained efforts in therapeutic innovation continue to boost the market's value and long-term growth potential.
Japan Tuberculosis Treatment Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Active TB to Dominate the Market Share Based on Disease Type
Based on disease type, the market is divided into active TB and latent TB. Among these, active tuberculosis is expected to hold a significant share of the market, driven by its higher transmission risk, symptomatic nature, and greater need for immediate medical intervention. The growing global burden of active TB cases and increased public health efforts for early detection and treatment further contribute to its dominant share in the tuberculosis treatment market.
Japan Tuberculosis Treatment Market Analysis by Region
The Japan tuberculosis treatment market shows strong regional performance, with the eastern and western regions leading due to their dense populations and well-established healthcare systems. Eastern Japan, including Tokyo and surrounding areas, drives demand through advanced medical facilities. Western Japan, particularly Osaka, contributes significantly through ongoing public health initiatives and increased awareness of tuberculosis screening and treatment.
Leading Players in the Japan Tuberculosis Treatment Market
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sanofi
Sanofi, established in 1973 and headquartered in Paris, France, is a global healthcare leader committed to developing innovative treatments. In the tuberculosis treatment market, Sanofi plays a significant role through its product Priftin® (rifapentine), used in combination with isoniazid for latent tuberculosis infection. The company’s long-standing investment in tuberculosis research strengthens its impact in the region.
Johnson and Johnson Services Inc.
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson Services Inc. plays a significant role in tuberculosis treatment through its product Sirturo (bedaquiline). Approved by the U.S. FDA and European Commission in July 2024, SIRTURO® is vital for treating multidrug-resistant tuberculosis and supports global treatment protocols, including those adopted in Japan.
Otsuka Pharmaceutical, Inc.
Otsuka Pharmaceutical Co., Ltd., established in 1964 and headquartered in Tokyo, Japan, is a global healthcare company actively involved in tuberculosis treatment. The company has developed Deltyba (delamanid), an innovative anti-tuberculosis drug used to treat multidrug-resistant TB. Through its research and development efforts, Otsuka continues to address critical needs in the tuberculosis treatment market.
GlaxoSmithKline plc
GlaxoSmithKline plc, headquartered in London, United Kingdom, plays a key role in tuberculosis treatment. The company joined the PAN-TB collaboration, a global initiative aimed at developing novel, simplified, and resistance-free tuberculosis regimens. This strategic involvement supports innovation in Japan's TB treatment market, addressing complex treatment challenges and drug-resistant cases.
Other key players in the market include Pfizer Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, and Eli Lilly and Company.
Key Questions Answered in the Japan Tuberculosis Treatment Market Report
Japan Tuberculosis Treatment Market Overview
Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially impacting other organs. Tuberculosis treatment involves a multi-drug antibiotic regimen over several months to ensure complete eradication and prevent resistance. The Japan tuberculosis treatment market is supported by robust healthcare systems, aging demographics, and national efforts in disease control and prevention.
Japan Tuberculosis Treatment Market Growth Drivers
Rising Tuberculosis Incidence to Accelerate Market Growth
The increasing incidence of tuberculosis is a significant driver of market growth in Japan. As per the World Health Organization, Japan recorded a tuberculosis incidence rate of 9.3 cases per 100,000 population in 2023. This ongoing public health concern reflects the demand for effective therapies, thereby contributing to the expansion of the tuberculosis treatment market.
Japan Tuberculosis Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Deployment of Mobile X-Ray Technology Likely to Elevate the Market Value
A notable trend in the market is the deployment of mobile diagnostic technology to support international public health. In August 2024, Japan provided a mobile X-ray machine to Olongapo City, Philippines, under its Official Development Assistance initiative. This strategic collaboration highlights Japan's technological contribution and is likely to boost market growth through innovation and global outreach.
Innovative Drug Development and Diagnostic Advancements to Augment the Japan Tuberculosis Treatment Market Demand
The Japan tuberculosis treatment market is experiencing a positive trend driven by historic innovation and ongoing diagnostic efforts. Since launching Pasnal and Iscotin in the mid-20th century, Daiichi Sankyo has remained a pioneer in tuberculosis drug development. These sustained efforts in therapeutic innovation continue to boost the market's value and long-term growth potential.
Japan Tuberculosis Treatment Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Active TB
- Latent TB
- First-Line Therapy
- Second-Line Therapy
- Tablets
- Capsules
- Injections
- Others
- Oral
- Parenteral
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Active TB to Dominate the Market Share Based on Disease Type
Based on disease type, the market is divided into active TB and latent TB. Among these, active tuberculosis is expected to hold a significant share of the market, driven by its higher transmission risk, symptomatic nature, and greater need for immediate medical intervention. The growing global burden of active TB cases and increased public health efforts for early detection and treatment further contribute to its dominant share in the tuberculosis treatment market.
Japan Tuberculosis Treatment Market Analysis by Region
The Japan tuberculosis treatment market shows strong regional performance, with the eastern and western regions leading due to their dense populations and well-established healthcare systems. Eastern Japan, including Tokyo and surrounding areas, drives demand through advanced medical facilities. Western Japan, particularly Osaka, contributes significantly through ongoing public health initiatives and increased awareness of tuberculosis screening and treatment.
Leading Players in the Japan Tuberculosis Treatment Market
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sanofi
Sanofi, established in 1973 and headquartered in Paris, France, is a global healthcare leader committed to developing innovative treatments. In the tuberculosis treatment market, Sanofi plays a significant role through its product Priftin® (rifapentine), used in combination with isoniazid for latent tuberculosis infection. The company’s long-standing investment in tuberculosis research strengthens its impact in the region.
Johnson and Johnson Services Inc.
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson Services Inc. plays a significant role in tuberculosis treatment through its product Sirturo (bedaquiline). Approved by the U.S. FDA and European Commission in July 2024, SIRTURO® is vital for treating multidrug-resistant tuberculosis and supports global treatment protocols, including those adopted in Japan.
Otsuka Pharmaceutical, Inc.
Otsuka Pharmaceutical Co., Ltd., established in 1964 and headquartered in Tokyo, Japan, is a global healthcare company actively involved in tuberculosis treatment. The company has developed Deltyba (delamanid), an innovative anti-tuberculosis drug used to treat multidrug-resistant TB. Through its research and development efforts, Otsuka continues to address critical needs in the tuberculosis treatment market.
GlaxoSmithKline plc
GlaxoSmithKline plc, headquartered in London, United Kingdom, plays a key role in tuberculosis treatment. The company joined the PAN-TB collaboration, a global initiative aimed at developing novel, simplified, and resistance-free tuberculosis regimens. This strategic involvement supports innovation in Japan's TB treatment market, addressing complex treatment challenges and drug-resistant cases.
Other key players in the market include Pfizer Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, and Eli Lilly and Company.
Key Questions Answered in the Japan Tuberculosis Treatment Market Report
- What was the Japan tuberculosis treatment market value in 2024?
- What is the Japan tuberculosis treatment market forecast outlook for 2025-2034?
- What is the market segmentation based on disease type?
- What is the market breakup based on the therapy?
- What is the market breakup based on the dosage form?
- How is the market segmented based on route of administration?
- How is the market divided based on the end user?
- What are the major factors aiding the Japan tuberculosis treatment market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Japan tuberculosis treatment market trends?
- Which disease type is expected to dominate the market segment?
- Which therapy is expected to dominate the market segment?
- Which dosage form is projected to lead the market segment?
- Which route of administration is anticipated to drive the market segment?
- Which end user is likely to dominate the market segment?
- Who are the key players involved in the Japan tuberculosis treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Tuberculosis Treatment Market Overview – Japan
- 3.1 Tuberculosis Treatment Market Historical Value (2018-2024)
- 3.2 Tuberculosis Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Tuberculosis Treatment Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Tuberculosis Treatment Market - Epidemiology Scenario and Forecast – Japan
- 7.1 Japan Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.3 Diagnosed Cases, by Country
- 7.4 Treatment Seeking Rate, by Country
- 8 Tuberculosis Treatment Market Landscape – Japan
- 8.1 Tuberculosis Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Tuberculosis Treatment Market: Product Landscape
- 8.2.1 Analysis by Disease Type
- 8.2.2 Analysis by Therapy
- 8.2.3 Analysis by Route of Administration
- 8.2.4 Analysis by Dosage Form
- 9 Clinical Trials and Pipeline Analysis
- 9.1 Analysis by Trial Registration Year
- 9.2 Analysis by Trial Status
- 9.3 Analysis by Trial Phase
- 9.4 Analysis by Therapeutic Area
- 9.5 Analysis by Geography
- 9.6 Drug Pipeline Analysis
- 10 Tuberculosis Treatment Market Challenges and Unmet Needs
- 10.1 Treatment Pathway Challenges
- 10.2 Compliance and Drop-Out Analysis
- 10.3 Awareness and Prevention Gaps
- 11 Cost of Treatment
- 12 Tuberculosis Treatment Market Dynamics
- 12.1 Market Drivers and Constraints
- 12.2 SWOT Analysis
- 12.2.1 Strengths
- 12.2.2 Weaknesses
- 12.2.3 Opportunities
- 12.2.4 Threats
- 12.3 PESTEL Analysis
- 12.3.1 Political
- 12.3.2 Economic
- 12.3.3 Social
- 12.3.4 Technological
- 12.3.5 Legal
- 12.3.6 Environment
- 12.4 Porter’s Five Forces Model
- 12.4.1 Bargaining Power of Suppliers
- 12.4.2 Bargaining Power of Buyers
- 12.4.3 Threat of New Entrants
- 12.4.4 Threat of Substitutes
- 12.4.5 Degree of Rivalry
- 12.5 Key Demand Indicators
- 12.6 Key Price Indicators
- 12.7 Industry Events, Initiatives, and Trends
- 12.8 Value Chain Analysis
- 13 Japan Tuberculosis Treatment Market (218-2034)
- 13.1 Japan Tuberculosis Treatment Market (2018-2034) by Disease Type
- 13.1.1 Market Overview
- 13.1.2 Active TB
- 13.1.3 Latent TB
- 13.2 Japan Tuberculosis Treatment Market (2018-2034) by Therapy
- 13.2.1 Market Overview
- 13.2.2 First-Line Therapy
- 13.2.3 Second-Line Therapy
- 13.3 Japan Tuberculosis Treatment Market (2018-2034) by Dosage Form
- 13.3.1 Market Overview
- 13.3.2 Tablets
- 13.3.3 Capsules
- 13.3.4 Injections
- 13.3.5 Others
- 13.4 Japan Tuberculosis Treatment Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Others
- 13.5 Japan Tuberculosis Treatment Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacies
- 13.5.3 Retail Pharmacies
- 13.5.4 Online Pharmacies
- 13.5.5 Others
- 14 Regulatory Framework
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication Year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 16 Grants Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Drug Class of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Drug Class of Partnership
- 18.3 Analysis by Leading Players
- 18.4 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis (Top 5 Companies)
- 19.2 Sanofi
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Company News and Development
- 19.2.5 Certifications
- 19.3 Pfizer Inc.
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Company News and Development
- 19.3.5 Certifications
- 19.4 Johnson and Johnson Services Inc.
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Company News and Development
- 19.4.5 Certifications
- 19.5 Otsuka Pharmaceutical, Inc
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Company News and Development
- 19.5.5 Certifications
- 19.6 Novartis AG
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Company News and Development
- 19.6.5 Certifications
- 19.7 GlaxoSmithKline plc
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Company News and Development
- 19.7.5 Certifications
- 19.8 Merck & Co., Inc.
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Company News and Development
- 19.8.5 Certifications
- 19.9 Teva Pharmaceutical Industries Ltd
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Company News and Development
- 19.9.5 Certifications
- 19.10 AstraZeneca plc
- 19.10.1 Financial Analysis
- 19.10.2 Product Portfolio
- 19.10.3 Demographic Reach and Achievements
- 19.10.4 Company News and Development
- 19.10.5 Certifications
- 19.11 Eli Lilly and Company
- 19.11.1 Financial Analysis
- 19.11.2 Product Portfolio
- 19.11.3 Demographic Reach and Achievements
- 19.11.4 Company News and Development
- 19.11.5 Certifications
- 20 Tuberculosis Treatment Market - Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 22 Payment Methods (Additional Insight)
- 22.1 Government Funded
- 22.2 Private Insurance
- 22.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
